Processing

Please wait...

Settings

Settings

Goto Application

1. WO2013144704 - IMMUNOMODULATING CYCLIC COMPOUNDS FROM THE BC LOOP OF HUMAN PD1

Publication Number WO/2013/144704
Publication Date 03.10.2013
International Application No. PCT/IB2013/000553
International Filing Date 28.03.2013
IPC
C07K 14/705 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
C07K 14/47 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
A61K 38/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
CPC
A61K 31/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 38/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
12Cyclic peptides ; , e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
A61K 38/1774
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
177Receptors; Cell surface antigens; Cell surface determinants
1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 31/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Applicants
  • AURIGENE DISCOVERY TECHNOLOGIES LIMITED [IN]/[IN]
Inventors
  • SASIKUMAR, Pottayil Govindan Nair
  • RAMACHANDRA, Muralidhara
Priority Data
1213/CHE/201229.03.2012IN
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) IMMUNOMODULATING CYCLIC COMPOUNDS FROM THE BC LOOP OF HUMAN PD1
(FR) COMPOSÉS CYCLIQUES D'IMMUNOMODULATION PROVENANT DE LA BOUCLE BC DE PD1 HUMAIN
Abstract
(EN) The present invention relates to novel cyclic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivative's of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.
(FR) La présente invention concerne de nouveaux composés cycliques en tant qu'agents thérapeutiques aptes à inhiber la voie de signalisation de la mort cellulaire programmée 1 (PD1). L'invention concerne également des dérivés des agents thérapeutiques. L'invention englobe également l'utilisation desdits agents thérapeutiques et dérivés pour le traitement de troubles par l'intermédiaire d'immunopotentialisation comprenant l'inhibition d'un signal immunosuppresseur induit en raison de PD-1, PD-L1 ou PD-L2, et des thérapies à l'aide de ceux-ci.
Latest bibliographic data on file with the International Bureau